Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
The University of Texas MD Anderson Cancer Center
Abstract
Abstract There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15) in 37 patients with CD19 + B cell malignancies. The primary objectives were safety and efficacy, defined as day 30 overall response (OR). Secondary objectives included day 100 response, progression-free survival, overall survival and CAR19/IL-15 NK cell persistence. No notable toxicities such as cytokine release syndrome, neurotoxicity or graft-versus-host disease were observed. The day 30 and day 100 OR rates…
Citation impact
- FWCI
- 110.30
- Percentile
- 100%
- References
- 79
Authors
36- DMDavid MarínCorresponding
The University of Texas MD Anderson Cancer Center
- YLYe Li
The University of Texas MD Anderson Cancer Center
- RBRafet Başar
The University of Texas MD Anderson Cancer Center
- HRHind Rafei
The University of Texas MD Anderson Cancer Center
- MDMay Daher
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Immunology
- CD19
- Chimeric antigen receptor
- Cord blood
- Biology
- Interleukin 21
- Immune system
- Natural killer cell
- Good health and well-being